April 25 (Reuters) - The U.S. Food and Drug Administration on Thursday sent a warning letter to Cardinal Health after an inspection of its facility in Illinois showed that the company was marketing unapproved devices. (Reporting by Pratik Jain in Bengaluru)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
98.88 USD | -0.84% | -4.34% | -3.04% |
05-07 | Cardinal Health Board of Directors Approves Increase to Quarterly Dividend, Payable on July 15, 2024 | CI |
05-07 | Deutsche Bank Adjusts Price Target on Cardinal Health to $110 From $116 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.04% | 24.29B | |
+17.39% | 71.72B | |
+7.71% | 8.31B | |
-19.61% | 8.22B | |
+1.47% | 8.16B | |
+5.56% | 4.76B | |
+15.41% | 4.31B | |
-0.87% | 4.1B | |
+23.20% | 3.78B | |
+6.89% | 3.36B |
- Stock Market
- Equities
- CAH Stock
- News Cardinal Health, Inc.
- US FDA sends warning to Cardinal Health for marketing unapproved devices